Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 3 Prostatic Neoplasms 2 Carcinoma, Transitional Cell 2 Urologic Neoplasms 1 Squamous Cell Lung Cancer 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuronopathy, Distal Hereditary Motor, Type IIB 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 346 Cisplatin 240 Paclitaxel 208 Radiotherapy 207 Pemetrexed 190 Docetaxel 170 Gemcitabine 158 pembrolizumab 147 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 102 Etoposide 99 Bevacizumab 96 Specimen Handling 84 Nivolumab 77 Radiosurgery 74 durvalumab 73 Blood Specimen Collection 65 Drug Therapy 61 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 48 atezolizumab 45 Biopsy 43 Radiation 42 Irinotecan 42 Topotecan 39 Standard of Care 39 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × apatorsen × Clear all

NCT01829113 2018-06-08

Spruce

SCRI Development Innovations, LLC

Phase 2 Completed

155 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡